`
`6/29/2017
`
`PubMed
`
`Format: Abstract
`
`Arch Soc Esp Oftalmol. 2000 Nov;75(11):751756.
`[Nonpreserved topical steroids and lacrimal punctal occlusion for severe keratoconjunctivitis
`sicca].
`[Article in Spanish]
`1
`Sainz De La Maza Serra M , Simón Castellvi C, Kabbani O.
`Author information
`
`Abstract
`To analyze the efficacy of topical nonpreserved steroids before punctal occlusion in the treatment of severe keratoconjunctivitis sicca
`PURPOSE:
`associated with Sjögren's syndrome.
`We performed a prospective study including 15 patients, 30 eyes, (group 1) treated with topical nonpreserved steroids for 2 weeks
`METHODS:
`and then punctal occlusion, and 15 patients, 30 eyes, (group 2) treated directly with punctal occlusion. Symptom severity (03+) and corneal
`fluorescein staining (09+) were evaluated after a week and after two months, and results were statistically compared between both groups with
`the t Student test.
`Symptom severity was negative in 67% of patients of group 1 and in 27% of patients of group 2 (p=0.0001 ) after a week, and in 80%
`RESULTS:
`of patients in group 1 and in 33% of patients of group 2 (p=0.0003) after 2 months. Corneal fluorescein staining was negative in 67% (OD) and
`73% (OI) of patients of group 1 and in 33% (AO) of patients of group 2 (p=0.0001, AO) after a week, and in 80% (AO) of patients of group 1 and
`in 60% of patients of group 2 (AO) (p=0.0001, AO) after 2 months. There were no patients with side effects or complications.
`Topical nonpreserved steroid therapy for two weeks before punctal occlusion is effective in controlling symptoms and corneal
`CONCLUSIONS:
`fluorescein staining in patients with severe keratoconjunctivitis sicca associated with Sjögren's syndrome.
`
`PMID: 11151264
`[Indexed for MEDLINE]
`
`Publication types, MeSH terms, Substances
`
`LinkOut more resources
`
`PubMed Commons
`
`0 comments
`
`PubMed Commons home
`
`How to join PubMed Commons
`
`https://www.ncbi.nlm.nih.gov/pubmed/11151264
`
`1/1
`
`MYLAN - EXHIBIT 1053
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`